Who created the dengue tetravalent vaccine or Dengvaxia?
Who created the dengue tetravalent vaccine or Dengvaxia?
One dengue vaccine has been licensed, Dengvaxia® (CYD-TDV), developed by Sanofi Pasteur.
What type of vaccine is Dengvaxia?
Sanofi Pasteur’s Dengvaxia (CYD-TDV) is a live attenuated tetravalent chimeric vaccine made using recombinant DNA technology by replacing the PrM (pre-membrane) and E (envelope) structural genes of yellow fever attenuated 17D strain vaccine with those from the four dengue serotypes.
What are the side effects of Dengvaxia?
Side effects of Dengvaxia include injection site reactions (such as redness, swelling, itchiness and pain), fever, headache, lethargy and muscle ache. These side effects were of mild to moderate severity and of short duration (0 to 3 days).
Is Dengvaxia approved in Malaysia?
Dengvaxia was granted a two-year conditional registration in October 2016 by the Drug Control Authority of Malaysia for post-registration study, with conditions to monitor long term risks, safety and efficacy over a wider population [30].
Why is there no dengue vaccine?
The program was stopped when Sanofi Pasteur advised the government that the vaccine could put previously uninfected people at a somewhat higher risk of a severe case of dengue fever.
Where is Dengvaxia used?
Approved under the same restrictions as its licence in Europe, Dengvaxia is authorised for use in dengue-endemic areas of the US, including Puerto Rico, Guam and American Samoa.
How many vaccines are needed for dengue?
Three doses of vaccine are required. Each shot is spaced 6 months apart.
How long does dengue immunity last?
After recovering from a first dengue infection, a person is protected from infection with the remaining three dengue serotypes for two to three months. Unfortunately, it is not long-term protection, and after that short period, a person can be infected with any of the remaining three dengue serotypes.
Is there dengue vaccine in Malaysia?
Dengvaxia® can be found in the market across 14 countries, including four South East Asian countries. Nevertheless, this vaccine has yet to be sold in the Malaysian market as it has been approved to be used solely for Phase IV clinical study [10].
Is there a vaccine against dengue?
Dengue Vaccine Globally A vaccine to prevent dengue (Dengvaxia®) is licensed and available in some countries for people aged 9 to 45 years. The World Health Organization recommends that the vaccine only be given to persons with confirmed previous dengue virus infection.